Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
409 stopped studies mapped to Mature B-Cell Non-Hodgkin Lymphoma and descendants · 88% state a reason
Over the 409 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00210392 | VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy | Phase 2 | terminated | Sep 21, 2005 | International Extranodal Lymphoma Study Group (IELSG) | After IELSG25A study amendment, patients subject of the present study were eligible for inclusion… | Other (stated, no rule matched) |
| NCT00060671 | Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's… | Phase 3 | terminated | May 12, 2003 | CTI BioPharma | not stated | Not stated |
| NCT01088763 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or… | Phase 1 | terminated | Mar 17, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00288067 | Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | terminated | Feb 7, 2006 | National Cancer Institute (NCI) | NCI stopped supplying fenretinide in November of 2012. | Other (stated, no rule matched) |
| NCT00594308 | In-Vivo Activated T-Cell Depletion to Prevent GVHD | N/A | terminated | Jan 15, 2008 | Indiana University | Treatment ineffective | Other (stated, no rule matched) |
| NCT01914718 | Dose-adjusted EPOCH-R in MYC Positive DLBCL | Phase 2 | terminated | Aug 2, 2013 | Fudan University | Poor accrual of eligible patients | Enrollment / accrual |
| NCT01005979 | A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of… | Phase 1 | terminated | Nov 2, 2009 | Emory University | Slow Accrual | Enrollment / accrual |
| NCT01397591 | Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell,… | Phase 2 | terminated | Jul 19, 2011 | OHSU Knight Cancer Institute | Study closed by PI due to lower than expected accrual. | Enrollment / accrual |
| NCT01534949 | Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to…(Triad-DLBCL) | Phase 1 | terminated | Feb 17, 2012 | Celltrion | not stated | Not stated |
| NCT01466868 | Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma(AKTIL) | Phase 2 | terminated | Nov 8, 2011 | Centre Leon Berard | Regarding the comments of the iDSMB, the sponsor decided to stop the inclusions | Sponsor / business decision |
| NCT00089076 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | Phase 1 / Phase 2 | terminated | Aug 5, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00100711 | Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or… | Phase 2 | terminated | Jan 5, 2005 | Pharmacyclics LLC. | not stated | Not stated |
| NCT00183976 | Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related… | Phase 2 | terminated | Sep 16, 2005 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT00183989 | Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma | Phase 2 | terminated | Sep 16, 2005 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT00383565 | FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | Phase 2 | terminated | Oct 3, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00510887 | Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular… | Phase 2 | terminated | Aug 2, 2007 | Duke University | Low accrual. | Enrollment / accrual |
| NCT00933985 | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane… | Phase 1 | terminated | Jul 8, 2009 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01902862 | An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard… | Phase 2 | terminated | Jul 18, 2013 | Janssen-Cilag G.m.b.H | Recruitment too slow | Enrollment / accrual |
| NCT00096005 | Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | Phase 1 | terminated | Nov 9, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00101205 | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or… | Phase 1 | terminated | Jan 10, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00308087 | Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed…(PREMIER) | Phase 2 | terminated | Mar 29, 2006 | Genzyme, a Sanofi Company | Terminated by sponsor due to low enrollment; see details below | Enrollment / accrual |
| NCT00019708 | Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's… | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01854372 | Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC)… | Phase 2 | withdrawn | May 15, 2013 | The University of Texas Health Science Center at San Antonio | not stated | Not stated |
| NCT00058461 | Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or… | Phase 2 | terminated | Apr 9, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00947388 | Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) | Phase 1 | terminated | Jul 28, 2009 | Case Comprehensive Cancer Center | No more eligible patients | Other (stated, no rule matched) |
| NCT00514722 | Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced… | N/A | terminated | Aug 10, 2007 | University of California, San Francisco | low accrual | Enrollment / accrual |
| NCT00003502 | Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma | Phase 2 | withdrawn | Jan 27, 2003 | Burzynski Research Institute | not stated | Not stated |
| NCT00377104 | Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small… | Phase 1 | terminated | Sep 15, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00079443 | FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With… | Phase 2 | terminated | Mar 10, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00776802 | GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory…(GCS-100LE) | Phase 1 / Phase 2 | withdrawn | Oct 21, 2008 | La Jolla Pharmaceutical Company | Lack of funding | Funding |
| NCT00009984 | Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer | Phase 2 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01238146 | Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With… | Phase 1 / Phase 2 | withdrawn | Nov 10, 2010 | National Cancer Institute (NCI) | No patients accrued. | Enrollment / accrual |
| NCT00103272 | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With… | Phase 1 | terminated | Feb 8, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00126191 | Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma | Phase 2 | terminated | Aug 3, 2005 | Dana-Farber Cancer Institute | closed due to slow accrual | Enrollment / accrual |
| NCT00354185 | PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic… | Phase 1 | terminated | Jul 20, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00005786 | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia | N/A | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00015912 | Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory… | Phase 2 | terminated | Oct 15, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00060112 | Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma | Phase 1 | terminated | May 7, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00005950 | 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell… | Phase 2 | terminated | Apr 20, 2004 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00101244 | SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's… | Phase 1 | terminated | Jan 10, 2005 | National Cancer Institute (NCI) | Administratively Complete. | Other (stated, no rule matched) |
| NCT00301795 | Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV… | Phase 2 | terminated | Mar 13, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00902525 | Zevalin Twice in Aggressive Non-Hodgkin Lymphoma | Phase 2 | terminated | May 15, 2009 | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie | After enrolling 25 patients an interim analysis was done.The study was discontinued in the absence… | Efficacy / futility |
| NCT00850499 | Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in… | Phase 2 | terminated | Feb 25, 2009 | Millennium Pharmaceuticals, Inc. | not stated | Not stated |
| NCT00541424 | Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma | — | withdrawn | Oct 10, 2007 | M.D. Anderson Cancer Center | No study recruitment due to time constraints and lack of support. | Enrollment / accrual |
| NCT00636155 | EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Phase 2 | terminated | Mar 14, 2008 | David Rizzieri | funding | Funding |
| NCT00968331 | Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients… | Phase 2 | terminated | Aug 31, 2009 | University of Bologna | The EC withdrawn the approval becuase of possible conflicts of interests between our Institute and… | Other (stated, no rule matched) |
| NCT00843050 | A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory… | Phase 2 | terminated | Feb 13, 2009 | Piramal Enterprises Limited | The study was terminated based on interim results and all subjects were off study at that time. No… | Safety / toxicity |
| NCT01558778 | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem… | N/A | withdrawn | Mar 20, 2012 | Roswell Park Cancer Institute | device not available | Other (stated, no rule matched) |
| NCT00475332 | Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar | Phase 2 | terminated | May 21, 2007 | University of Florida | PI left our institution | Investigator |
| NCT00107614 | DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's… | Phase 2 | terminated | Apr 6, 2005 | University of Arkansas | Terminated due to poor accrual. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Mar 30, 2015source: clinicaltrials